| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/31/2002 | WO2002008271A1 Novel fibroblast growth factor (fgf23) and methods for use |
| 01/31/2002 | WO2002008267A2 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 01/31/2002 | WO2002008264A2 Papillomavirus infected epithelial cells and methods of producing infectious papillomavirus in epithelial cells and uses thereof |
| 01/31/2002 | WO2002008262A2 Bstp-5 proteins and related reagents and methods of use thereof |
| 01/31/2002 | WO2002008261A2 Bstp-trans protein and related reagents and methods of use thereof |
| 01/31/2002 | WO2002007813A1 Vaccines |
| 01/31/2002 | WO2002007764A1 Improvements relating to vaccines containing bordetella pertussis antigen |
| 01/31/2002 | WO2002007752A2 Red blood cell as vehicle for agent-membrane translocation sequence conjugate |
| 01/31/2002 | WO2002007730A1 Alpha v integrin receptor antagonists |
| 01/31/2002 | WO2001080873A3 Thrombopoietin receptor modulating peptide |
| 01/31/2002 | WO2001068146A3 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| 01/31/2002 | WO2001064244A3 In ovo protection against infectious bronchitis |
| 01/31/2002 | WO2001062940A3 New phosphodiesterase type 7b |
| 01/31/2002 | WO2001062801A3 Humanized antibodies that sequester amyloid beta peptide |
| 01/31/2002 | WO2001062784A3 Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer |
| 01/31/2002 | WO2001061017A3 Modified cytokines for use in cancer therapy |
| 01/31/2002 | WO2001057075A3 Virulence genes, proteins, and their use |
| 01/31/2002 | WO2001057065A3 Combinatorial protein domains |
| 01/31/2002 | WO2001052887A3 Vaccination against canine herpesvirus infection and vaccines |
| 01/31/2002 | WO2001049716A3 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| 01/31/2002 | WO2001049243A3 Veto cells effective in preventing graft rejection and devoid of graft versus host potential |
| 01/31/2002 | WO2001048485A3 Selecting library members capable of binding to epitopes |
| 01/31/2002 | WO2001040473A3 Pseudomonas aeruginosa antigens |
| 01/31/2002 | WO2001039778A3 Triazinone compounds for treating diseases resulting from infestation with parasitic protozoans |
| 01/31/2002 | WO2001034801A3 Recombinant gelatin in vaccines |
| 01/31/2002 | WO2001031343A3 Diagnosis and therapy of cancer using sgp28-related molecules |
| 01/31/2002 | WO2001026681A3 Method of obtaining cellular immune responses from proteins |
| 01/31/2002 | WO2001008634A3 Polynucleotide encoding a human serine protease |
| 01/31/2002 | WO2000059941A9 Purposeful movement of human migratory cells away from an agent source |
| 01/31/2002 | WO2000057910A9 Attenuated dengue-4 virus vaccine |
| 01/31/2002 | WO1998021343A8 Genes encoding telomerase proteins |
| 01/31/2002 | US20020013456 Cortistatin: neuropeptides, compositions and methods |
| 01/31/2002 | US20020013286 Administering the adenoviral gene transfer vector (exogenous) encoding a gene product to a muscle and the vector is neutralized outside of the muscle by systemic neutralizing antibodies; using a chimeric coat protein for cell entry |
| 01/31/2002 | US20020013285 Nucleosome-based anti-tumor compositions |
| 01/31/2002 | US20020013274 Administering a covalently reactive antigen analog (CRAA) having an an epitope recognized irreversibly bound by catalytic antibody; autoimmune disease; a lymphoproliferative disorder; anticarcinogenic, -tumor, -inflammatory agents |
| 01/31/2002 | US20020012965 Nucleotide sequences coding prfeerential polypeptides for use in the diagnosis and treatment of brain disorders and injury |
| 01/31/2002 | US20020012963 Nucleotide sequences coding preferential peptides; for use in diagnosing and treatment of allergies |
| 01/31/2002 | US20020012954 Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth |
| 01/31/2002 | US20020012931 High specificity marker detection |
| 01/31/2002 | US20020012919 Nucleic acids of rochalimaea henselae and methods and compositions for diagnosing rochalimaea henselae and rochalimaea quintana infection |
| 01/31/2002 | US20020012696 In gene therapy and in in vitro and in vivo transfection |
| 01/31/2002 | US20020012673 Immunstimulating lipid formulation |
| 01/31/2002 | US20020012672 For immunization of domestic fowl, such as turkeys and chickens, against E. coli infections (Colibacillosis) |
| 01/31/2002 | US20020012671 Channel forming toxins as antiviral agents |
| 01/31/2002 | US20020012668 Used in diagnostics, detection of the bacteria Salmonella.typhi or in the production of vaccines for typhoid fever |
| 01/31/2002 | US20020012667 Method for preventing allograft rejection |
| 01/31/2002 | US20020012666 Administering to animal an egg product wherein the egg product is obtained from an egg-producing animal which has been hyperimmunized with an immunogenic vaccine |
| 01/31/2002 | US20020012665 Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma |
| 01/31/2002 | US20020012664 Combining agent to be tested, antibody or antigen-binding fragment which binds to amino terminal domain of mammalian CC-chemokine receptor 2, mammalian CC-chemokine receptor 2 or ligand-binding variant, measuring binding |
| 01/31/2002 | US20020012663 Inhibiting the growth of refractory tumors that are stimulated by a ligand of epidermal growth factor receptor (EGFR) in human patients, comprising treating the human patients with an effective amount of an EGFR/HER1 antagonist |
| 01/31/2002 | US20020012661 Methods for introducing genes into mammalian subjects |
| 01/31/2002 | US20020012658 Prevention and treatment of verotoxin-induced disease |
| 01/31/2002 | DE10053783A1 Modifying antigen-presenting cells, useful e.g. in antitumor vaccines, by transfer to them of antigen-containing membrane fragments from diseased cells |
| 01/31/2002 | CA2797652A1 Multi-component biological transport systems |
| 01/31/2002 | CA2418333A1 Bicistronic influenza comprising two genes in tandem |
| 01/31/2002 | CA2418282A1 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 01/31/2002 | CA2418215A1 Novel fibroblast growth factor (fgf23) and methods for use |
| 01/31/2002 | CA2417185A1 Multivalent target binding protein |
| 01/31/2002 | CA2416751A1 Alpha v integrin receptor antagonists |
| 01/31/2002 | CA2416733A1 Nk cells activating receptors and their therapeutic and diagnostic uses |
| 01/31/2002 | CA2416657A1 Fh-binding protein of streptococcus pneumoniae |
| 01/31/2002 | CA2416538A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/31/2002 | CA2416488A1 Codon-optimized papilloma virus sequences |
| 01/31/2002 | CA2412626A1 Il-17 molecules and uses thereof |
| 01/31/2002 | CA2412544A1 Polypeptide delivery ii-2 |
| 01/30/2002 | EP1176201A2 Platelet-specific chimeric immunoglobulin |
| 01/30/2002 | EP1176200A2 Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases or wound healing and their use in indentifying pharmacologically acitve substances |
| 01/30/2002 | EP1176195A1 Method for controlling the activity of immunologically functional molecule |
| 01/30/2002 | EP1176193A1 Inhibitors for viral infection targeting integrase n-terminal region |
| 01/30/2002 | EP1176192A2 Helicobacter felis vaccine |
| 01/30/2002 | EP1175912A1 Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
| 01/30/2002 | EP1175909A2 Therapeutic methods and compositions based on serrate proteins and nucleic acids |
| 01/30/2002 | EP1175616A1 Methods for the diagnosis and treatment of metastatic prostate tumors |
| 01/30/2002 | EP1175513A1 MinK-RELATED GENES, FORMATION OF POTASSIUM CHANNELS AND ASSOCIATION WITH CARDIAC ARRHYTHMIA |
| 01/30/2002 | EP1175503A1 49 human secreted proteins |
| 01/30/2002 | EP1175497A2 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| 01/30/2002 | EP1175486A2 Method for the preservation of viruses and mycoplasma |
| 01/30/2002 | EP1175446A1 Human antibodies that bind human il-12 and methods for producing |
| 01/30/2002 | EP1175445A1 Specific antibodies and antibody fragments for tgfbeta1 |
| 01/30/2002 | EP1175437A2 Vaccine |
| 01/30/2002 | EP1175227A1 Monoclonal antibody directed against cells of human renal cell carcinoma |
| 01/30/2002 | EP1175226A1 Lipoglycan compositions and methods of treating parasitic infections |
| 01/30/2002 | EP1175224A2 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy |
| 01/30/2002 | EP1175144A2 Orally immunogenic bacterial enterotoxins expressed in transgenic plants |
| 01/30/2002 | EP0614355B1 Antitumor vaccines |
| 01/30/2002 | CN1333873A HIV-specfic T-cell induction |
| 01/30/2002 | CN1333832A Compounds and methods for treatment and diagnosis of chlamydial infection |
| 01/30/2002 | CN1333830A Compositions and methods for therapy and diagnosis of ovarian cancer |
| 01/30/2002 | CN1333829A Polypeptide |
| 01/30/2002 | CN1333757A Quinazoline derivatives as medicaments |
| 01/30/2002 | CN1333693A ordered molecualr presentation of antigens, method of preparation and use |
| 01/30/2002 | CN1333378A Diagnose test |
| 01/29/2002 | US6343258 Method for testing for readiness for harvesting of tribulus terrestris l. having high steroidal saponin content |
| 01/29/2002 | US6342584 Antiproliferative, anticarcinogenic, antitumor, antiinflammatory, and antimetastasis agents; diabetes, restenosis, rheumatoid arthritis treatment; genetic engineering |
| 01/29/2002 | US6342392 Isolation of human and murine wild-type int6 gene cdna; cancer diagnosis; gene and immunotherapy; vaccines; gene expression |
| 01/29/2002 | US6342383 Reverse transcriptase activity; endogenous retroviruses |
| 01/29/2002 | US6342382 Purified nucleic acid; complementarity; washing follow hybridization; genetic engineering and expression |
| 01/29/2002 | US6342352 Method of detecting shigella and shigella mxiM DNA |
| 01/29/2002 | US6342234 Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence |
| 01/29/2002 | US6342232 For prophylaxis of otitis media |